MiNK Therapeutics, Inc. INKT 深 滬
已收盤 02-06 16:00:00 美东时间
10.97
-0.050
-0.45%
華盛通- 最 高11.35
- 今 開11.1865
- 成交量 1.27万股
- 最 低 10.825
- 昨 收 11.02
- 總市值 5149.49万
- 52周最高 76.00
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 6.34
- 委 比 71.43%
- 總股本 469.42万
- 歷史最高 221.55
- 量 比 0.99
- 振 幅 4.76%
- 歷史最低 4.632
- 每 手 1
- 風險率 5.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reported Earlier, MiNK Therapeutics Highlights Depletion Of iNKT Cells In Advanced IPF At Keystone Symposia, Showcasing Potential For Disease-Modifying Therapy
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK's iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a
02-04 16:42
MiNK Therapeutics Plans To Initiate Phase 1 Clinical Study To Evaluate Safety, Tolerability Of AgenT-797 To Treat Graft-Versus-Host Disease, Relapse, Other Post-Transplant Complications In Patients With High-Risk Leukemias
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (allo-iNKT) cell therapies, today announced the upcoming initiation of a
01-09 01:06
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Shares of Fonar Corp (NASDAQ:FONR) rose sharply in pre-market after the company...
2025-12-30 17:43
电话会总结 ｜ MiNK Therapeutics (INKT) 业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据MiNK Therapeutics业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至季度末现金余额为1,430万美元，季度结束后额外筹集120万美元，总计现金储备1,550万美元，预计可支撑运营至2026年。 **净亏损情况：** - 季度净亏损：290万美元（每股0.65美元） - 九个月净亏损：990万美元（每股2.39美元） **营收情况：** 业绩会实录中未披露具体营收数据，公司目前仍处于临床试验阶段，主要为研发支出。 ## 2. 财务指标变化 **净亏损同比变化：** - 季度净亏损同比增长61.1%
2025-11-15 12:09
MiNK Therapeutics Q3 EPS $(0.65) Misses $(0.61) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.61) by 5.69 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from
2025-11-14 21:23
Earnings Scheduled For November 14, 2025
Companies Reporting Before The Bell • Inhibrx Biosciences (NASDAQ:INBX) is expe...
2025-11-14 19:11
MiNK Therapeutics Presents Updated Clinical Results Evaluating Agent-797, Alone And In Combination With Anti-PD-1 Therapy, In Patients With Advanced Solid Tumors Refractory To All Approved Treatments At SITC 2025
Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune remodeling
2025-11-07 22:07
MiNK Therapeutics Announces That Late-Breaking Phase 1 Data For Its Allogeneic iNKT Cell Therapy, AgenT-797, Will Be Presented At 40th Annual SITC Meeting Nov 7–9, 2025
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that
2025-10-30 21:03
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
MiNK Therapeutics appointed Colonel (Ret.) John B. Holcomb, MD, a global leader in trauma and critical care, to its Board of Directors. Dr. Holcomb brings extensive expertise in immune activation and clinical trial execution, reinforcing MiNK’s commitment to advancing iNKT cell therapies for immune-mediated diseases, pulmonary disorders, and global health security. His leadership will support the company’s mission to address urgent health challen...
2025-09-29 11:30
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
MiNK Therapeutics' CEO, Dr. Jennifer Buell, is set to deliver a plenary address at the 10th Annual CAR-TCR Summit in Boston, where she will present groundbreaking data on the company's iNKT cell therapies. Dr. Buell will discuss how these therapies achieve durable disease reversal and steroid-free remission in severe immune collapse, and how MiNK's translational strategy aims to accelerate development in non-oncology indications.
2025-09-25 11:30
